Overview
HIV I & II Antibodies (ELISA method) is a serological screening test used to detect antibodies produced against Human Immunodeficiency Virus type 1 and type 2. HIV-1 is the most common strain worldwide and is responsible for the global pandemic, while HIV-2 is mainly seen in West Africa and is associated with slower disease progression. ELISA is preferred because of its high sensitivity, ability to detect both HIV-1 and HIV-2 antibodies, low cost, and suitability for large-scale screening. Newer fourth- and fifth-generation ELISA tests can detect both HIV antibodies and p24 antigen, significantly reducing the window period.
Symptoms
The presence of HIV antibodies does not itself cause symptoms, but individuals being tested may present with features suggestive of HIV infection. Early infection may cause fever, rash, sore throat, lymphadenopathy, headache, and myalgia. As the disease progresses, patients may develop weight loss, chronic diarrhea, recurrent infections, prolonged fever, night sweats, oral candidiasis, and opportunistic infections. Many individuals remain asymptomatic for long periods and are identified only through screening.
Causes
HIV I & II antibodies are produced when the immune system responds to infection with HIV following exposure through unprotected sexual contact, transfusion of infected blood, sharing of contaminated needles, occupational exposure, or mother-to-child transmission.
ELISA detects these antibodies by binding them to HIV antigens coated on microplate wells, followed by enzyme-linked detection and color development. A reactive result indicates exposure to HIV but always requires confirmatory testing using more specific methods.
Risk Factors
Risk factors for HIV I & II Antibodies (Elisa Method) positivity include unprotected sexual activity, multiple sexual partners, intravenous drug use, exposure to contaminated blood or blood products, occupational exposure in healthcare workers, and vertical transmission from an infected mother. Individuals from high-prevalence regions, sex workers, men who have sex with men, and partners of HIV-positive individuals are at increased risk.
Testing during the window period of 3–12 weeks may result in false-negative results.
Prevention
Prevention of HIV infection relies on safe sexual practices, consistent condom use, screening of blood and blood products, use of sterile needles, and prevention of mother-to-child transmission through antenatal screening and treatment. Early screening using ELISA allows timely diagnosis and linkage to care. Adherence to antiretroviral therapy reduces viral load, improves survival, and prevents transmission. Regular testing of high-risk individuals and proper counseling before and after testing play a key role in controlling the spread of HIV.
